CJC-1295 vs PE 22-28
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of CJC-1295 and PE 22-28 (also searched as PE 22-28 vs CJC-1295) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
CJC-1295 centers on muscle, while PE 22-28 leans toward metabolic. On indexed research, PE 22-28 is ahead (CJC-1295: 4 studies, Preclinical; PE 22-28: 5, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •CJC-1295 is strongest for muscle; PE 22-28 for metabolic.
- •Evidence: CJC-1295 Preclinical (4 studies) vs PE 22-28 Human evidence (5).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
CJC-1295 vs PE 22-28: side-by-side
| Metric | CJC-1295 | PE 22-28 |
|---|---|---|
| Class | — | Cognitive |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Preclinical | Human evidence |
| Studies indexed | 4 | 5 |
| Research level | — | Emerging |
| Strongest effect | Muscle & body comp | Metabolic & appetite |
| Healing & recovery | 2.0▲ | 2.0▲ |
| Muscle & body comp | 4.0▲ | 0.0 |
| Metabolic & appetite | 3.0 | 4.0▲ |
| Neuro & mood | 2.0 | 3.0▲ |
| Sleep & circadian | 3.0▲ | 0.0 |
| Inflammation & immune | 1.0 | 2.0▲ |
| Skin & aesthetics | 1.0▲ | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | CJC-1295 | PE 22-28 |
|---|---|---|
| Mechanism | GHRH (1–29) analog, modified | — |
| Route | Subcutaneous injection | — |
| Half-life | ~30 min | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is CJC-1295?
GHRH analogue used in research contexts for GH/IGF-1 modulation, muscle and bone density, sleep, and recovery.
Full CJC-1295 profile, mechanism & studies →What is PE 22-28?
### Summary PE 22-28 is a peptide that has garnered attention in various research contexts, particularly in relation to vascular health and metabolic conditions. Its potential implications in gestational diabetes and placental function are areas of ongoing investigation.
Full PE 22-28 profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Even | Both ~2.0/5 |
| Muscle | CJC-1295 | 4.0/5 effect signal |
| Metabolic | PE 22-28 | 4.0/5 effect signal |
| Neuro | PE 22-28 | 3.0/5 effect signal |
| Sleep | CJC-1295 | 3.0/5 effect signal |
| Inflammation | PE 22-28 | 2.0/5 effect signal |
| Skin | CJC-1295 | 1.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack CJC-1295 and PE 22-28?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
CJC-1295 vs PE 22-28: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
CJC-1295 has 4 approved studies indexed (Preclinical), and PE 22-28 has 5 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is CJC-1295 or PE 22-28 better?
It depends on your goal. CJC-1295 is strongest for muscle; PE 22-28 for metabolic. PE 22-28 has more indexed studies (5). See the goal-by-goal breakdown above.
Is CJC-1295 or PE 22-28 better for weight loss?
PE 22-28 shows the stronger metabolic & appetite profile (4.0/5) in community effect data — though weight-loss outcomes depend on the individual and the evidence base.
Is CJC-1295 or PE 22-28 better for muscle?
CJC-1295 leads on the muscle & body-composition axis (4.0/5).
Which has more research, CJC-1295 or PE 22-28?
CJC-1295 has 4 approved studies indexed (Preclinical); PE 22-28 has 5 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack CJC-1295 and PE 22-28?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of CJC-1295 vs PE 22-28?
CJC-1295: no community-reported effects logged yet. PE 22-28: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is CJC-1295 or PE 22-28 FDA-approved?
CJC-1295 is a research-use compound and is not FDA-approved. PE 22-28 is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is PE 22-28 better than CJC-1295?
For metabolic, PE 22-28 has the edge; for muscle, CJC-1295 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
CJC-1295 and PE 22-28 are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.